S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:NXTC

NextCure Stock Forecast, Price & News

$11.44
+0.49 (+4.47 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.86
Now: $11.44
$11.76
50-Day Range
$9.66
MA: $10.58
$12.43
52-Week Range
$7.91
Now: $11.44
$70.98
Volume362,566 shs
Average Volume454,337 shs
Market Capitalization$315.21 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.53
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900
Employees69

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.35 million
Book Value$14.13 per share

Profitability

Net Income$-33,740,000.00

Miscellaneous

Market Cap$315.21 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$11.44
+0.49 (+4.47 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NextCure (NASDAQ:NXTC) Frequently Asked Questions

How has NextCure's stock price been impacted by Coronavirus?

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NXTC stock has decreased by 70.1% and is now trading at $11.44.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NextCure?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NextCure?

Wall Street analysts have given NextCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NextCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for NextCure
.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.59) EPS for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.02. NextCure had a negative return on equity of 8.43% and a negative net margin of 65.22%.
View NextCure's earnings history
.

What price target have analysts set for NXTC?

8 analysts have issued 12 month price objectives for NextCure's stock. Their forecasts range from $11.00 to $55.00. On average, they expect NextCure's stock price to reach $26.67 in the next year. This suggests a possible upside of 133.1% from the stock's current price.
View analysts' price targets for NextCure
.

Are investors shorting NextCure?

NextCure saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,100,000 shares, a decline of 42.1% from the October 31st total of 1,900,000 shares. Based on an average trading volume of 385,300 shares, the short-interest ratio is presently 2.9 days. Approximately 6.4% of the shares of the company are short sold.
View NextCure's Short Interest
.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

Who are NextCure's key executives?

NextCure's management team includes the following people:
  • Mr. Michael S. Richman, Co-Founder, CEO, Pres & Director (Age 59, Pay $625.68k)
  • Dr. Solomon Langermann, Chief Scientific Officer (Age 61, Pay $459.11k)
  • Dr. Lieping Chen M.D., Ph.D., Co-Founder & Chairman of Scientific Advisory Board (Age 63)
  • Mr. Steven P. Cobourn CPA, CPA, Chief Financial Officer (Age 57)
  • Dr. Timothy Mayer Ph.D., Chief Operating Officer (Age 56)
  • Dr. Linda N. Liu, Sr. VP of Research (Age 54)
  • Dr. James B. Bingham Ph.D., Chief Devel. Officer (Age 54)

When did NextCure IPO?

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Canaan Partners X LLC (6.22%), BlackRock Inc. (4.47%), Morgan Stanley (3.88%), ArrowMark Colorado Holdings LLC (2.62%), JPMorgan Chase & Co. (0.46%) and Charles Schwab Investment Management Inc. (0.32%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure
.

Which institutional investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners X LLC, Victory Capital Management Inc., ArrowMark Colorado Holdings LLC, Virtus ETF Advisers LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for NextCure
.

Which institutional investors are buying NextCure stock?

NXTC stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, Cubist Systematic Strategies LLC, Boothbay Fund Management LLC, and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure
.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $11.44.

How big of a company is NextCure?

NextCure has a market capitalization of $315.21 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. NextCure employs 69 workers across the globe.

What is NextCure's official website?

The official website for NextCure is www.nextcure.com.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.